Latest Boehringer Ingelheim Stories
- Effects of idarucizumab on an exploratory marker of blood clotting, presented at the American Heart Association's Scientific Sessions RIDGEFIELD, Conn., Nov.
- Jardiance® (empagliflozin) data results presented at the 2014 Scientific Sessions of the American Heart Association RIDGEFIELD, Conn. and INDIANAPOLIS, Nov.
CAMBRIDGE, Mass., Nov.
- RE-VERSE AD(TM) is being conducted in more than 35 countries with aim to enroll 250 patients RIDGEFIELD, Conn., Nov. 10, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc.
- Poster on research about investigational, specific antidote for PRADAXA also to be presented RIDGEFIELD, Conn., Nov. 10, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc.
Case Funding Company reaffirms increased funding amounts for Pradaxa Pre-Settlement and Settled Cases after $650MM settlement on approximately 4K filed cases over the blood thinner in state and federal
RIDGEFIELD, Conn., Nov. 3, 2014 /PRNewswire/ -- Boehringer Ingelheim today announced that the U.S.
Significant portion of alliance opportunity will remain unchanged; some countries will transition to exclusive promotion in 2015 INDIANAPOLIS and INGELHEIM, Germany, Oct.
LONDON and BOSTON, October 28, 2014 /PRNewswire/ -- Global top 20 pharma company streamlines R&D IT with cross-domain platform Boehringer Ingelheim,
Data for the co-administration of Spiriva® HandiHaler® (tiotropium bromide inhalation powder) + Striverdi® Respimat® (olodaterol) Inhalation Spray presented at CHEST 2014 RIDGEFIELD,
- The word or words serving to define another word or expression, as in a dictionary entry.